TRAW

#4798
Traws Pharma, Inc. - Common Stock
0.5 9 USD
0.00%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
0.58
0.59
Intervallo Annuale
0.43
3.25
Variazione giornaliera
0.00%
Variazione Mensile
+31.11%
Variazione di 6 mesi
-64.24%
Variazione Annuale
-55.97%
Chiusura Precedente
0.5 9
Open
0.5 8
Minimo
0.5 8
Massimo
0.5 9
Volume
13
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Traws Pharma, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K

Traws Pharma, Inc. current report, Q3 FY2018

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Onconova Therapeutics, Inc. (not Traws Pharma, Inc.) on September 25, 2018. The filing reports the effective implementation of a reverse stock split approved by stockholders at the June 27, 2018 Annual Meeting. The company is an emerging growth company incorporated in Delaware.

Key Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure adjustments.

Material Changes

  • Reverse Stock Split: A one-for-fifteen reverse stock split became effective on September 25, 2018.
  • Share Count Reduction: Outstanding common shares decreased from approximately 85.11 million to approximately 5.67 million.
  • Authorized Shares: The number of authorized shares remains at 250,000,000.
  • Trading Symbol: The stock continues to trade on the NASDAQ Capital Market under the symbol ONTX, with split-adjusted trading beginning September 26, 2018.
  • Warrant Adjustments: Tradable warrants (symbol ONTXW) were adjusted. Each warrant now entitles the holder to purchase 1/15 of a share at an exercise price of $73.80 per share.
  • Fractional Shares: No fractional shares were issued; holders entitled to fractions received a full share. Warrant exercise fractions are rounded down.

Guidance, Outlook, and Risks

The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the mechanics of the stock split. The primary operational change is the adjustment of the capital structure to comply with exchange listing requirements or shareholder preferences.

Investor Verification Checklist

  • Verify the new CUSIP number for the common stock: 68232V 405.
  • Confirm the adjusted exercise price and share quantity for any held tradable warrants (1/15 share at $73.80).
  • Check the post-split share count of approximately 5.67 million shares.
  • Review the attached Certificate of Amendment (Exhibit 3.1) for legal details on the reclassification.
  • Monitor the NASDAQ Capital Market for the commencement of split-adjusted trading on September 26, 2018.